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Abstract
Identifying subgroups of patients with an enhanced response to a new treatment has become an
area of increased interest in the last few years. When there is knowledge about possible subpopulations
with an enhanced treatment effect before the start of a trial it might be beneficial to set up a testing
strategy, which tests for a significant treatment effect not only in the full population, but also in these
prespecified subpopulations. In this paper we present a parametric multiple testing approach for tests
in multiple populations for dose-finding trials. Our approach is based on the MCP-Mod methodol-
ogy, which uses multiple comparison procedures to test for a dose-response signal, while considering
multiple possible candidate dose-response shapes. Our proposed methods allow for heteroscedasticity
between populations and control the FWER over tests in multiple populations and for multiple can-
didate models. We show in simulations, that the proposed multi-population testing approaches can
increase the power to detect a significant dose-response signal over the standard single-population
MCP-Mod, when the considered subpopulation has an enhanced treatment effect.
Keywords: MCP-Mod; Multiple Testing; Subgroup Analyses; Targeted Therapies
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1 Introduction
Identifying subgroups of patients with an enhanced response to a new treatment has become an area of
increased interest in the last few years. Hence subgroup analyses are commonly performed all throughout
the clinical development process. In many cases these analyses are performed in an exploratory fashion
and a large number of possible subgroups are considered with the aim to find a patient population, in
which the treatment is particularly effective. For these scenarios many novel subgroup identification and
treatment effect estimation methods have been proposed see, for example, [1, 2, 3, 4, 5, 6] or [7]. An
extensive overview over exploratory subgroup analysis methods is given in [8].
When such an exploratory subgroup analysis results in a promising subgroup finding, this subgroup
could then be used in a future trial. Alternatively such a subgroup could be identified before the start
of a trial based on clinical expert knowledge. In these situation it might be beneficial to plan the trial
with the subgroup in mind and test for a treatment effect in both the full population and the subgroup.
Depending on the result of the trial there are then three possible positive outcomes: (i) the drug is shown
to be efficacious for all patients, (ii) the drug is shown to be efficacious only in a subgroup or (iii) the drug
is shown to be efficacious for all patients but with an increased efficacy for patients in a subgroup. In the
last scenario there might be uncertainty about the effect in the full population, since it could be driven
by the large effect in the subgroup and the rest of the population could have negligible treatment effects.
One can consider an additional test in the complement to avoid this issue.
For the design of trials, in which subpopulations are of interest, additional considerations have to
be made regarding the power of the tests and possible trial designs like enrichment or adaptive designs.
Some of these considerations regarding the power when testing in the whole population and a subgroup
are discussed in [9] and [10]. [11] discuss several different enrichment and adaptive designs.
When tests are performed in multiple populations multiplicity has to be taken in to account to avoid
an inflated type I error. It is possible to use non-parametric approaches to control multiplicity, as for
example, Bonferroni or Holm-corrections, or more complex stepwise procedures as discussed in [12].
However non-parametric methods would ignore the correlations between test statistics that arise, when
tests are performed in the overall population and a subgroup, where the latter is a subset of the former.
Using a parametric approach can be more efficient and show an increase in power over the aforementioned
methods. Such parametric approaches are for example discussed in [10] and [13].
In addition to testing in multiple populations a clinical trial might also investigate multiple doses of
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the same treatment. Dose-finding trials are routinely performed in Phase II of clinical development and in
some cases Phase III trials also investigate several different doses of the same treatment. Frequently there
might be uncertainty about the underlying dose-response shape and thus which dose-response model to
fit to the data. Subgroup identification methods in the context of dose-response trials have recently been
introduced in [14] and a testing approach, that can be used for dose-response-trials with a prespecified
subgroup would be useful in practice as well. In this paper we want to propose such an approach, which
is based on the MCP-Mod methodology ([15]).
The MCP-Mod approach combines multiple comparison procedures and modeling to analyse dose-
response trials. MCP-Mod consists of two parts. In the multiple comparisons procedure (MCP) step
a test for a dose-response signal is performed for several prespecified candidate dose-response shapes .
The contrasts for the tests are chosen to achieve optimal power for the tests. MCP-Mod uses the joint
distribution of the test statistics to control the family-wise error rate (FWER) at a specified level, while
accounting for the correlations between test statistics. In case of a normally distributed outcome the joint
distribution of the tests statistics is known and the correlation structure between the test statistics depends
on the candidate shapes used. The more general case, which is described in [16] extends the framework
to non-normal outcomes using the asymptotic distribution of the test statistics. If a dose-response signal
is established under any of the considered shapes, one can continue to the second step, the modeling part.
In the modeling (Mod) step significant models can then be fit to the data and be used for dose estimation.
Further details concerning the design and analysis of clinical trials with MCP-Mod are discussed in [17]
and [18].
The approach we propose in this paper is an extension of the MCP-part of the MCP-Mod methodology
to allow for testing for a dose-response signal in multiple populations. We specifically focus on the
situation of a Phase II trial, where there is uncertainty about the underlying dose-response shape and
a subgroup with a possibly enhanced treatment effect has been prespecified. The proposed methods
adjust for the multiplicity resulting from tests for different dose-response shapes and tests in multiple
populations, and make use of the correlation between the tests. We also take into account, that variance
might differ between populations. While we focus on tests in one subgroup and the full population, in
general the methodology presented here can be used to perform multiple comparisons across arbitrarily
overlapping populations of any number, while controlling the FWER.
The remainder of this paper is structured as follows: In the following Section we will present the
methodology to perform contrast tests in multiple populations. In Section 3 we show the results of
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simulations, which evaluate the operating characteristics of the approach, focusing on FWER control and
power. In Section 4 we summarize and discuss the results.
2 Multiple contrast tests for multiple populations
2.1 Notation, models and contrast tests
We consider a clinical trial, which has been performed in parallel groups of patients, which receive dif-
ferent doses d1, d2, ..., dk of an experimental treatment. The number of patients in the dose groups are
n1, ..., nk and n :=
k∑
i=1
ni, the total number of patients in the study. We observe responses Y , which can
either be related to efficacy or safety of the new treatment. In the following we distinguish between three
populations of interest: the full or overall population (F ), which includes all patients, and two prespecified
subpopulations of F ; a subpopulation of patients, which has been identified to possibly show an enhanced
treatment effect (S) and the complement of that subpopulation (C), so that F = S ∪ C. To simplify the
discussion of the methodology we introduce the two index sets, U := {F, S, C} and V := {S,C}. In
what follows we assume that the patients can be classified into subgroup and complement without error.
We adopt the general framework from [15], but additionally introduce the population as an additional
component in the models. Analogously to the original MCP-Mod framework we therefore consider the
model
Y
(P )
ij = f(di,θ)
(P ) + 
(P )
ij ; 
(P )
ij ∼ N(0, σ2P ) i.i.d,
i = 1, ..., k, j = 1, ..., n
(P )
i , P ∈ V
(1)
where θ refers to the vector of model parameters, i to the dose group and j to the patient within dose
group i and population P . n(P )i denotes the number of patients in population P , which are in dose
group i, so that ni = n
(F )
i = n
(S)
i + n
(C)
i . To simplify the discussion we assume that the prevalence
of the subgroup is deterministic and constant across all dose levels. We denote the prevalence of S by
γ :=
n
(S)
1
n
(F )
1
= · · · = n
(S)
k
n
(F )
k
. A more general discussion without the assumption of constant prevalences is
included in the Appendix.
Model (1) is assumed to be the underlying dose-response model with regard to dose estimation. For
the contrast tests, which have the aim of detecting a dose-response relationship, a different model,
Y
(P )
ij = µ
(P )
i + 
(P )
ij ; 
(P )
ij ∼ N(0, σ2P ) i.i.d,
i = 1, ..., k, j = 1, ..., n
(P )
i , P ∈ V
(2)
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is considered. µ(P )i is the mean response for dose group i in population P . An estimate for µ
(P )
i is the
arithmetic mean Y¯i
(P )
=
n
(P )
i∑
j=1
Y
(P )
ij
n
(P )
i
. For population P we denote the vector of the estimated dose means
by Y¯ (P ) = (Y¯1
(P )
, . . . , Y¯k
(P )
)
′ . Additionally the pooled variance estimator for σ2P is
S(P )
2
=
k∑
i=1
n
(P )
i∑
j=1
(Y
(P )
ij − Y¯i(P ))2/
k∑
i=1
(n
(P )
i − k). (3)
We assume uncertainty regarding the underlying shape of the dose-response relationship and assume,
that a set of plausible candidate models {M1, . . . ,MZ} is prespecified. These models are candidates to
describe the shape of the dose-response curve and produce mean vectors under the alternative. Usually
candidate models are commonly encountered dose-response models like Emax, linear, exponential or
quadratic shapes. These candidate models are used to obtain the contrast vectors for the tests. Contrast
vectors cm
′
= (cm1, . . . , cmk) are chosen optimally to guarantee maximal power for each single contrast
test. For details on choosing the optimal contrasts see [15].
The MCP-Mod approach then tries to detect a significant dose-response relationship for at least one
of the models. In theory it is possible to specify a different set of candidate shapes for each population.
We assume here, that the set of candidate models is the same across all populations, which is likely
plausible for most real-life situations. With this assumption and the assumption of a constant prevalence
of the subgroups across all dose groups the optimal contrast vectors are independent of the population, in
which the test is performed. We discuss the more general situation of different candidate models across
populations in the Appendix.
For each candidate model m ∈ {M1, . . . ,MZ} and each population P ∈ U a contrast test testing
the null hypothesis H(P,m)0 : cm
′
µ(P ) = 0 against the alternatives H(P,m)1 : cm
′
µ(P ) > 0 is performed.
Using this alternative we assume without loss of generality, that the treatment effect will have a positive
sign.
In total the number of tests is 3Z. We define the population null hypothesis (in P ) as
H
(P )
0 : H
(P,M1)
0 ∩ ... ∩H(P,MZ)0 ,
the intersection of the null hypotheses for all candidate models in population P . The global null hypothe-
sis is then the intersection between the population null hypotheses, in all tested populations. For example
for the full testing strategy, which includes both subgroup and complement the global null hypothesis is
H
(global)
0 : H
(F )
0 ∩H(S)0 ∩H(C)0
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While rejecting the global null is of main interest, the population hypotheses have to be considered to
determine if a dose-response trend has been established in all populations or, for example, only in a
subgroup.
The test statistics are contrast tests of the form
T (P )m =
(cm)
′
Y¯
(P )√
(σˆ(P ))2
k∑
i=1
c2mi/n
(P )
i
m ∈ {M1, . . . ,MZ}, P ∈ V, (4)
which are performed for each of the candidate models in each population. (σˆ(P ))2 is an estimator of
the variance in population P . There are several estimators that could be considered. Which estimator
to use depends on the assumptions made regarding possible heteroscedasticity between subgroup and
complement and has an effect on the critical values used for the tests as we will discuss in the following.
If the variances in subgroup and complement are assumed to be the same, e.g. we assume homoscedas-
ticity between populations, we can drop the population indices for the variances. Then σ2S = σ
2
C = σ
2.
We can then also drop the population index from the variance estimator in (4) and use the same estimator
for all tests. A pooled variances estimator (pooled over dose levels and over subgroup and complement)
is the natural choice in this context, since model (2) assumes that the means are different both across dose
levels, and subgroup and complement. The pooled variance estimator is then
σˆ2 =
∑
P∈V
k∑
i=1
n
(P )
i∑
j=1
(Y
(P )
ij − Y¯i(P ))2/
∑
P∈V
(
k∑
i=1
n
(P )
i − k). (5)
The assumption of homogeneous variances in all populations may not always be justified. For example
patients in a subgroup might be assumed to be more homogeneous than patients in the full population and
thus the subgroup will be assumed to have smaller variances. If we assume the variances in subgroup
and complement to be unequal, e.g. we assume heteroscedasticity between subgroup and complement
(σ2S 6= σ2C) the pooled variance estimator will generally be biased and different estimators should be used.
When heteroscedasticity is assumed, it is more appropriate to estimate the variance separately in
subgroup and complement. In each population a variance estimate, which is pooled over the dose levels
as in (5) can then be used. Then (σˆ(S))2 = (S(S))2 and (σˆ(C))2 = (S(C))2.
Under the global null hypothesis there is no difference between contrasts in subgroup and comple-
ment (both are assumed to be zero). Under these assumptions a weighted average of the two popula-
tion variance estimates is a reasonable estimator for the variance in the full population. For the tests
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in the full population under assumed heteroscedasticity we would therefore use the variance estimator
(σˆ(F ))2 = 1
n
· [
k∑
i=1
n
(S)
i (σˆ
(S))2 +
k∑
i=1
n
(C)
i (σˆ
(C))2)].
2.2 FWER control
Performing multiple tests at once, as in the approach we described above, leads to multiplicity issues. In
the classic MCP-Mod approach the family-wise error rate (FWER) across all tests is controlled, e.g. the
probability to reject at least one true null hypothesis is below a specified level α. The MCP-Mod approach
makes use of the joint distribution of the test statistics to obtain critical values or adjusted p-values. In
the situation we consider here, in addition to the multiplicity stemming from testing different candidate
shapes, there is also multiplicity stemming from tests in several populations. When MCP-Mod is per-
formed in only one population, the joint distribution is known to be multivariate t under the assumptions
of model (2). When considering multiple populations the joint distribution of the test statistics is only
multivariate t, if the variance is assumed to be equal across all populations.
In the following discussion we assume that tests are performed in the full population, the subgroup and
the complement, since this is the most complete testing strategy and the distributions for other strategies
can easily be derived from this.
We will first consider the homoscedastic case, where variances are assumed to be equal in subgroup
and complement (σ2S = σ
2
C = σ
2). Then it is appropriate to use the pooled variance estimate (5) in
all populations and the vector of test statistics T ′ = (T (F )M1 , . . . , T
(F )
MZ
, T
(S)
M1
, . . . , T
(S)
MZ
, T
(C)
M1
, . . . , T
(C)
MZ
) is
distributed as MV T3Z(ν,0,R) with ν =
∑
P∈V
(
k∑
i=1
n
(P )
i − k) degrees of freedom, mean vector 0 and
correlation matrixR. The correlation matrix has the form
R =

RFF RFS RFC
R
′
FS RSS RSC
R
′
FC R
′
SC RCC
 ,
where the entries of submatrixRPQ ∈ RZ×Z for P,Q ∈ U are given as
(ρij)
(PQ) =
K∑
l=1
cilcjl · n(P∩Q)l /(n(P )l n(Q)l )√
K∑
l=1
cil2/n
(P )
l
K∑
l=1
cjl2/n
(Q)
l
, i, j = 1, . . . , Z.
Based on the above formula it is easily visible, that RSC = 0, since subgroup and complement are
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distinct. The other submatrices are easily obtainable as well, for example
(ρij)
(FS) =
√
γ ·
k∑
l=1
cilcjl/n
(F )
l√
k∑
l=1
cil2/n
(F )
l
k∑
l=1
cjl2/n
(F )
l
, i, j = 1, . . . , Z
follows for the entries of the matrixRFS .
The joint distribution for performing tests only in the full population and in the subgroup without a
separate test in the complement can easily be derived by dropping the irrelevant test statistics from the
vector T ′ and removing the irrelevant submatrices (in this case the last row and column) from R. Using
the quantiles of the joint distribution as critical values for the tests will then guarantee strong control of
the FWER over the population null hypotheses.
If variances cannot assumed to be equal in subgroup and complement, the situation becomes more
challenging. In this case the variance estimator in the denominator of the test statistics (4) is population-
dependent and the degrees of freedoms of the t-distributions are no longer the same in all populations.
Therefore the joint distribution is not multivariate t and in fact does not seem to belong to any standard
probability distribution. The terms in the correlation matrix R also become more complex, since the
variance terms no longer cancel out for all of the submatrices. In general the correlation submatrices then
have entries
(ρij)
(PQ) =
K∑
l=1
cilcjl·(n(P∩Q∩S)l σ2S+n
(P∩Q∩C)
l σ
2
C)/(n
(P )
l n
(Q)
l )√
K∑
l=1
{cil2·(n(P∩S)l σ2S+n
(P∩C)
l σ
2
C)/n
(P )
l
2}
K∑
l=1
{cjl2·(n(Q∩S)l σ2S+n
(Q∩C)
l σ
2
C)/n
(Q)
l
2}
,
i, j = 1, . . . , Z;P,Q ∈ U.
For example for the entries of submatrixRFS we get
(ρij)
(FS) =
σS
K∑
l=1
cilcjl/n
(F )
l√
[γσ2S + (1− γ)σ2C ]
K∑
l=1
cil2/n
(F )
l
K∑
l=1
cjl2/n
(S)
l
, i, j = 1, . . . , Z.
The variances σ2S and σ
2
C are usually unknown. To obtain the correlation matrix, the estimates for σ
2
S and
σ2C can be plugged into the formulas above.
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Table 1: Overview over considered MCPs with the variance estimates used in the test statistics, the
distribution used to obtain critical values and the degrees of freedom for the multivariate t distributions.
Here ν(P ) :=
k∑
i=1
n
(P )
i − k, the degrees of freedom for population P .
Method Description Variance estimation Distribution Degrees of freedom
SP Standard MCP in
single (full) population
pooled multivariate t
k∑
i=1
n
(F )
i − k
MP-Pooled Multi-population MCP
assuming homoscedasticity
pooled multivariate t
∑
P∈V
k∑
i=1
ν(P )
MP-MinDF Multi-population MCP
assuming heteroscedasticity
population-specific multivariate t
(approx.)
min
P∈V
ν(P )
MP-MultDF Multi-population MCP
assuming heteroscedasticity
population-specific multivariate t
(approx.)
ν(P ) (different
for each population)
MP-Normal Multi-population MCP
assuming heteroscedasticity
population-specific multivariate normal
(approx.)
-
There are several reasonable options to approximate the joint distribution of the tests statistics under
heteroscedasticity and obtain multiplicity-adjusted p-values. A simple solution is to assume that the vari-
ances are known and use the multivariate normal distribution to obtain p-values and critical values. Since
the multivariate t distribution approaches a multivariate normal distribution as n→∞ this approximation
will work well for reasonably large sample sizes.
For small sample sizes a conservative option is to use the smallest degrees of freedom across all
populations, νmin := min
P∈V
ν(P ), where ν(P ) :=
k∑
i=1
n
(P )
i −k are the population specific degrees of freedom.
In the considered setting this is equivalent to using the degrees of freedom from the population with the
smallest number of patients. Then a MV T3Z(νmin,0,R) - distribution can be used as an approximate
joint distribution.
A less conservative approximation, which is proposed in [19] is to use a multiple degrees of freedom
approximation, which translates to using a different multivariate t-distribution with the correct degrees
of freedom for each population to obtain critical values. E.g. for test statistics from population P ∈ U ,
T
(P )
M1
, . . . , T
(P )
MZ
, the critical values are obtained from a MV T3Z(ν(P ),0,R) - distribution. A similar ap-
proach has also been discussed by [20] for standard (non-contrast) t-tests in subgroups, while additionally
allowing for non-fixed sample sizes in subgroups.
Table 1 summarizes all discussed methods both under the assumption of homoscedasticity and het-
eroscedasticity.
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3 Simulation study
In this section we discuss results of a simulation study to evaluate the properties of the multi-population
testing approaches. The simulation setup is similar to the one used in [15]. The simulations are divided
into two main parts. In the first part (Section 3.2) we assume homoscedasticity across populations and
evaluate the power of the proposed multi- population testing approaches compared to the standard single
population MCP, which only considers the full population. The second part (Section 3.3) deals with the
scenario of heteroscedastic populations. In addition to the comparison of multi-population MCP to single
population MCP the main focus of this Section is to evaluate the different considered procedures, which
are based on approximations of the joint distribution, with regard to FWER control and power.
3.1 Simulation setup
We simulate clinical trials with parallel groups, which are balanced over the dose levels. In our simulated
trial patients are randomized to one of five different dose groups with dose levels 0, 0.05, 0.2, 0.6, 1. We
assume that there is knowledge about a subgroup, which possibly shows an enhanced treatment effect and
could have been identified from an earlier trial or based on the mode of action of the drug. We also make
the simplifying assumption, that for each dose group the proportion of patients in the subgroup is equal.
Together with the assumption of a balanced trial design, this means, that n(S)1 = · · · = n(S)k .
We generate the observed data for the simulated trials from models of the form
Y
(P )
ij = f(di,θ)
(P ) + 
(P )
ij ; 
(P )
ij ∼ N(0, σ2P ) i.i.d,
i = 1, ..., k, j = 1, ..., n
(P )
i , P ∈ V
(6)
and use common dose-response shapes for f . An overview over the used dose-response shapes is given
in Table 2. We also include a constant model to generate data under the global null hypothesis. The
subgroup we simulate has prevalences γ of either 0.25, 0.5 or 0.75. We assume that the underlying shape
is the same for subgroup and complement. However the ’slope’ parameters of the model, which are not
fixed (see Table 2) can vary between populations. This allows us to simulate scenarios with different
treatment effects between subgroup and complement.
We consider three scenarios for how the treatment effect is distributed between subgroup and comple-
ment. In the first scenario there is no enhanced effect in the subgroup, e.g. the treatment effect is identical
in the subgroup and the complement (same-scenario). In the second scenario the treatment effect in the
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Table 2: Data generating dose-response models and corresponding standardized versions, which are used
as candidate shapes to determine optimal contrast tests. Parameters specified in the last column are fixed
for all simulated trials and are used as guesstimates to derive optimal contrasts.
Model f(d,θ) standardized model fixed parameters
Constant 0.2 - -
Emax θ0 + θ1d(θ2+d)
d
(θ2+d)
θ0 = 0.2; θ2 = 0.2
Linear θ0 + θ1d d θ0 = 0.2
Exponential θ0 + θ1 · exp[ dθ2 − 1] exp[ dθ2 − 1] θ2 = 0.29
Logistic θ0 + θ11+exp[(θ2−d)/θ3
1
1+exp[(θ2−d)/θ3 θ2 = 0.4; θ3 = 0.091
Quadratic θ0 + θ1d+ θ2d2 d+ θ2|θ1|d
2 θ1
θ2
= 1.171
subgroup is double the size of the effect in the complement (double-scenario). Finally for the third and
last scenario there is only a treatment effect in the subgroup and the treatment effect in the complement
is zero (only-scenario). The three different scenarios represent situations, in which there is in reality no
subgroup and possible treatment effects are constant across the full population (same) , or in which a
treatment effect in the full population is driven mostly (double) or completely (only) by a large effect in
the subgroup.
We choose the (non-fixed) parameters for the non-constant models, so that the treatment effect at the
highest dose is 0.6, which leads to a power of 80% (for a pairwise comparison) for a group size of 75.
For the same-scenario 0.6 is the treatment effect in the full population, for the only- and double-scenarios
it is the treatment effect in the subgroup. This leads to scenarios, where the treatment effect is relatively
large in the subgroup but possibly hard to detect (depending on γ) in the full population.
For the multiple comparison procedure we then perform tests for all non-constant shapes in Table 2
in all populations we consider, irrespective of which of the shapes was used for data-generation. For the
multi-population MCP approaches we compare two different testing strategies. These testing strategies
differ with regards to the populations in which tests are performed. Tests are performed either in the full
population and the subgroup (F + S) or in full population, subgroup and the complement (F + S + C).
The first strategy would be used in a situation, where there is information about a possibly existing
subgroup, which could potentially have an enhanced treatment effect. The second strategy could be
applied in a similar situation, but could additionally be used to confirm that the treatment effect in the full
population is not only driven by a subgroup with an enhanced effect. If the test could also be rejected
11
in the complement then this would confirm that there is consistency across the whole population with
regards to the treatment effects.
3.2 Homoscedastic scenarios
We will first discuss the simulation results for equal variances in subgroup and in the complement. For
these simulations we fix the standard deviations at σS = σC = 1.478. The results discussed in this Section
are based on 5000 simulated trials. In the article only selected results are shown. Complete simulation
results for all data-generating models are included in the Supporting Information.
In the homoscedastic case the exact joint distributions of the test statistics can be used to obtain critical
values or adjusted p-values for the individual tests as described in Section 2.2. Since the exact distribution
of the tests statistics is known, FWER is controlled at the nominal 5%-level for all testing methods, when
data are generated under the global null hypothesis, from a constant model. This is confirmed in the
simulation results, when data are generated from a constant model (shown in Supporting Information).
When we simulate data under the alternative of an existing dose-response trend, the MP testing ap-
proach with tests in full population and subgroup increases the chance of rejecting the global null hypoth-
esis, when the treatment effect only exists in the subgroup or is doubled in the subgroup. This is visualized
for data generated from an Emax model in Figure 1. The MP approach with tests in all populations (F + S
+ C) also shows more rejections than SP in the only-scenario. In the same-scenario SP rejects most often,
but the loss in power for the MP methods is relatively small, especially when the subgroup is large.
l l l
l
l
l
l
l
l
same effect in subgroup double effect in subgroup only effect in subgroup
0.25 0.5 0.75 0.25 0.5 0.75 0.25 0.5 0.75
0.25
0.50
0.75
1.00
prevalence of S
pr
ob
.
 
to
 re
jec
t g
lob
al 
nu
ll 
hy
p.
method
l SP
MP(F+S)
MP(F+S+C)
Figure 1: Probability to reject the global null hypothesis for single population (SP) and multi-population
(MP) testing methods. Data are generated from an Emax model under homoscedasticity.
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For the MP methods it might additionally be of interest, for which population(s) a significant dose-
response relationship is declared. For example a significant result only in the subgroup, but not in the
full population or the complement might lead to very different conclusions than significant results in all
populations. Population specific rejection results for data generated from Emax models are summarized
in Table 3. The results show that when the treatment effect only exists in the subgroup, the null hypothesis
in the subgroup is rejected up to 24% more often than the null hypothesis in the full population. The null
hypothesis for the complement, which is true in the only-scenario is only rejected in 2% of simulations.
When the treatment effect in the subgroup is doubled over the complement rejections generally occur
more often in the full population than in the subgroup. The difference decreases with increasing subgroup
prevalence γ. Table 3 also includes the results for the MP-MultDF method, which would also allow for
possible heteroscedasticity. The results are essentially the same as for MP-Pooled, there does not seem to
be a big penalty for allowing for heteroscedasticity in homoscedastic scenarios.
One of the main features of the discussed methods is the possibility to test for several possible dose-
response shapes. Hence it is also of interest to compare the model selection performance of the MP
testing approaches compared to the SP-MCP. Table 5 in the appendix shows the probability of choosing
the correct model for the different methods. The probability of choosing the correct model based on the
lowest significant p-value is almost identical between SP and MP approaches and therefore testing in
multiple populations does not seem to reduce the model selection performance.
3.3 Heteroscedastic scenarios
In this part we will show simulation results, when testing in multiple populations with different variances.
Here we use σS = 1.03 and σC = 1.926 for the standard deviations in subgroup and complement. The
combined standard deviation in the full population thus remains the same as before at 1.478, as long as
subgroup and complement have equal prevalence (γ = 0.5).
As discussed in Section 2.2 the joint distribution of the contrast test statistics does not follow a stan-
dard distribution, when variances are heterogeneous and instead approximations to the true joint distri-
bution are necessary to obtain critical values. In these simulations we will therefore first compare the
different possible approximations we discuss in Section 2.2. We focus on FWER control and power for
the considered approximations. For these simulations we increased the number of simulations from 5000
to 25000, to ensure that possible differences between the methods are distinguishable from simulation
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Table 3: Probability to reject the global null hypothesis and population null hypotheses for single popu-
lation (SP) and multi-population (MP) testing methods. Data are generated from an Emax model under
homoscedasticity.
Scenario and Prevalence
same same same double double double only only only
Method Hypothesis 0.25 0.5 0.75 0.25 0.5 0.75 0.25 0.5 0.75
SP global 0.88 0.88 0.88 0.55 0.69 0.79 0.16 0.40 0.66
MP-Pooled(F+S) global 0.84 0.84 0.86 0.54 0.70 0.81 0.34 0.59 0.75
F 0.82 0.82 0.85 0.44 0.60 0.74 0.11 0.31 0.60
S 0.31 0.55 0.73 0.30 0.54 0.73 0.30 0.55 0.72
MP-Pooled(F+S+C) global 0.83 0.82 0.83 0.51 0.65 0.75 0.30 0.52 0.68
F 0.79 0.77 0.79 0.40 0.55 0.67 0.09 0.26 0.53
S 0.28 0.47 0.66 0.27 0.48 0.67 0.26 0.49 0.65
C 0.65 0.47 0.27 0.21 0.15 0.08 0.02 0.02 0.02
MP-MultDF(F+S) global 0.83 0.84 0.87 0.53 0.69 0.80 0.35 0.59 0.76
F 0.81 0.82 0.85 0.42 0.59 0.74 0.12 0.32 0.60
S 0.28 0.53 0.72 0.30 0.54 0.73 0.30 0.55 0.72
MP-MultDF(F+S+C) global 0.83 0.82 0.83 0.49 0.64 0.75 0.31 0.53 0.69
F 0.78 0.77 0.79 0.38 0.53 0.67 0.10 0.27 0.52
S 0.25 0.47 0.65 0.26 0.47 0.66 0.27 0.48 0.64
C 0.65 0.47 0.26 0.20 0.14 0.08 0.02 0.02 0.02
error.
The approaches we consider for approximating the joint distribution are MP-MinDF, MP-MultDF
and MP-Normal (see Table 1). All of these approaches use separate variance estimates for the tests
in subgroup and complement. To evaluate the general necessity of using population-specific variance
estimates we also include test statistics using the pooled variance estimate (MP-Pooled), which assumes,
that variances are the same in subgroup and complement.
Figure 2 shows the probability of rejecting the global null hypothesis when the global null is true,
e.g. data are generated from a constant model. MP-Pooled, which ignores heteroscedasticity, generally
does not control the FWER at the nominal level, since the variance in the complement is underestimated,
when the subgroup is large. For a subgroup with prevalence of 0.75 the FWER is generally above 0.1
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with the pooled variance estimate. Of the three approximations, which use population-specific variance
estimates, MP-Normal is as expected liberal and leads to a large inflation of the FWER for small sample
sizes. For large sample sizes MP-Normal approximates the true joint distribution better and the FWER
is close to the nominal level. Of the two remaining approaches, which use approximate multivariate t
distributions, the MP-MinDF approach controls the FWER rate at the nominal level for all sample sizes
and prevalences. MP-MultDF shows similar error rates but shows FWERs slightly higher than 0.05 for
very small sample sizes.
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Figure 2: Probability to reject the global null hypothesis for different multi-population (MP) testing
methods. Data are generated from a constant model under heteroscedasticity. Tests were performed in
full population, subgroup and complement. Bars show the 95% - confidence intervals (accounting for
simulation error).
Figure 3 visualizes the differences with regards to power, e.g. the frequency of rejections of the global
null hypothesis for data generated from an Emax model for different scenarios and subgroup prevalences.
With pooled variance estimation the power is generally reduced compared to the other methods. The
approaches using population-specific variances estimates show fairly similar power, with MP-Normal
being more liberal for small sample sizes and therefore rejecting more often. The MP-MultDF approach
always leads to slightly more rejections than the MP-MinDF approach. The conclusions for the other
data-generating dose-response models are similar, detailed results for these models can be found in the
Supporting Information. Finally it is of interest to compare the multi-population testing strategies to the
single population MCP in the heteroscedastic setting as well. We focus here on the MP-MultDF approach,
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Figure 3: Probability to reject the global null hypothesis for different multi-population (MP) testing
methods. Data are generated from an Emax model under heteroscedasticity. Tests were performed in full
population, subgroup and complement.
since it gives FWER control roughly at the nominal level, while not sacrificing too much power. Figure 4
compares the methods for a sample size of 60 per group. Comparing Figure 4 to Figure 1 the differences
are now even larger between SP and MP methods. Since SP does not account for the different variances in
subgroup and complement, the MP methods give better power even when there is no increased treatment
effect in the subgroup and the treatment effect is the same for all patients.
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Figure 4: Probability to reject the global null hypothesis for single population (SP) and multi-population
(MP) testing methods. Data are generated from an Emax model under heteroscedasticity. MP-MultDF is
used to approximate the joint distribution for MP testing methods.
4 Discussion
In this paper we discussed an extension of the MCP part of the MCP-Mod methodology to allow for
testing in multiple populations. We focused on the situation of a dose-response trial, where a subgroup
with a suspected enhanced treatment effect has been prespecified. Our method allows for simultaneous
testing in full population, subgroup and possibly complement under model uncertainty, while controlling
the FWER across all candidate models and populations. Our simulation results in Section 3.2 and 3.3
show, that an increase in power of rejecting the global null hypothesis can be achieved, when using the
multi-population approach. The results suggest, that the prevalence of the subgroup and the size of the
treatment effect in the subgroup relative to the complement are important factors to determine if a multi-
population approach is worth considering. Additional plots, which visualize the effects of these factors
on the power in more detail are included in the Supporting Information.
Instead of considering the power, one can also use sample size calculations to illustrate the potential
benefits of a multi-population testing approach. Table 4 shows the sample sizes needed to achieve 80%
power for rejecting the global null hypothesis under the scenarios considered for the simulation study
in Section 3. For situations, where the subgroup has a strongly enhanced effect over the rest of the
population, the sample sizes for the trial can be significantly reduced when using a multi-population
approach instead of a single-population approach.
In the heteroscedastic case, the simulation results discussed in 3.3 show, that the multiple degrees of
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Table 4: Sample sizes (per dose) required to achieve 80% power for rejecting the global null hypothesis for
single population (SP) and multi-population (MP) testing methods. Required sample sizes are calculated
under the assumption of homoscedasticity across populations.
Scenario and Prevalence
same same same double double double only only only
Method 0.25 0.5 0.75 0.25 0.5 0.75 0.25 0.5 0.75
SP 59 60 59 151 105 77 932 235 105
MP-Pooled(F+S) 70 67 63 151 101 75 275 131 84
MP-Pooled(F+S+C) 71 70 70 163 112 87 299 147 97
freedom approach seems to result in a good approximation to the joint distribution of the test statistics.
The FWER-inflation is minimal compared to the multivariate normal approximation, which is only suit-
able for large sample sizes. Additionally, the multiple degrees of freedom approach sacrifices less power
than the conservative minimum degrees of freedom approach.
In the introduction we stated three different outcomes for a trial in multiple populations: (i) the drug
is shown to be efficacious for all patients, (ii) the drug is shown to be efficacious only in a subgroup or
(iii) the drug is shown to be efficacious for all patients but with an increased efficacy for patients in a
subgroup. The methodology we present here can be used to help with decision-making in this context.
We would advise to use our methodology together with estimates of treatment effects in the different
populations to decide which of the three outcomes is achieved. [21] propose a decision framework for
testing in a subgroup and the full population to arrive at one of the three conclusions.
We focused on scenarios, where a single subgroup and possibly the complement were considered for
testing apart from the full population. Nevertheless the methodology we present here is not restricted to
this setting and can be used to test in an arbitrary number of populations. We extend the method to more
general scenarios in the Appendix in Section A.1. While one could therefore include a large number of
subgroups and use the presented methodology to identify subgroups with an enhanced effect, we would
like to point out that in contrast to other subgroup identification approaches our method does not test
for an interaction between subgroup and treatment. A significant result in a subgroup does therefore not
necessarily indicate, that the subgroup shows a differential effect and could be caused by a treatment
effect, that is large but constant across all populations. Still, there are certain outcomes, which can be
indicative of a subgroup with a larger treatment effect, most notably, when the population null hypothesis
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for the subgroup is rejected but the population null hypothesis for the full population is not. In our
simulations this can be seen for some scenarios in Table 3. For scenarios, where there is only an effect in
the subgroup, the null hypothesis for the subgroup is more often rejected than for the full population.
We only consider normally distributed outcomes in this article. The MCP-Mod methodology has
been generalized to other types of outcomes in [16]. It is possible to apply the presented methodology
to general parametric models. In the general case of MCP-Mod the approximate multivariate normal
distribution is used. We already use this approximation in this article in Section 3.3 and show that it is a
reasonable approximation for large sample sizes. The correlation matrices we discuss in Section 2.2 can
simply be used for the multivariate normal instead of the multivariate t in the general case.
The testing procedure discussed here is a single-step test. Alternatively a sequentially rejective test
using the closed testing principle could be used as well. A similar procedure is discussed for the single-
populaton MCP-Mod in [22]. Furthermore, similarly as in [13], the multiple testing procedure can be
generalized to a weighted test and extended to a graph-based closed testing procedure.
The approach we present here only extends the MCP-part of MCP-Mod to multiple populations,
ignoring the modeling part. In the standard MCP-Mod either the dose-response model with the lowest
p-value is used for dose estimation or all significant models are combined via model averaging. Similar
solutions in the multi-population scenario could be fitting the model with an interaction term for the
subgroup, if the subgroup is significant, or using a model averaging approach that also includes subgroups,
as for example discussed in [23]. Extending the modeling part of the methodology to trials with multiple
populations therefore remains as an area for further research.
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Appendix
A.1. Joint distribution in the general case
In this Section we derive the correlation matrix for the joint distribution of the contrast tests. We will derive the
matrix for a general case with an arbitrary number of populations and also include the possibility that different
candidate shapes are tested in each population. The scenarios described in 2.2 are special cases of what we discuss
in this Section.
We assume that we have W populations that we consider for testing. These populations are contained in the
family U := {P1, . . . , PW }, where each population P ∈ U is a set of patients, so that P ⊂ {1, . . . , n}. As in the
main part of the article we need to introduce a second family of pairwise disjoint populations V := {P ∗1 , . . . , P ∗W ∗},
so that
W ∗⋃
r=1
P ∗r = {1, . . . , n}, if we want to allow for populations with different variances. We then assume that our
responses come from the model
Y
(P ∗)
ij = µ
(P ∗)
i + 
(P ∗)
ij ; 
(P ∗)
ij ∼ N(0, σ2P ∗) i.i.d,
i = 1, ..., k, j = 1, ..., n
(P ∗)
i , P
∗ ∈ V
(7)
and the vector of responses is Y = (Y11, ..., Y1n1 , ..., YK1, ..., YKnK ) with Cov(Y ) := ΣY . We therefore allow
each population in V to have a different variance. We need to make the distinction between V and U , since
the populations in U need not necessarily be pairwise disjoint. For example in the main article, subgroup and
complement are in both families but the full population is only in U .
We now assume that in each population P ∈ U we test for ZP different candidate shapes. In each population
P we therefore perform tests of H(P,m)0 : c
(P )
m
′
µ(P ) = 0 against the alternatives H(P,m)1 : c
(P )
m
′
µ(P ) > 0, for
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m = 1, . . . , ZP . The test statistics for these hypotheses are then
T (P )m =
(c(P )m )
′
Y¯
(P )√
(σˆ(P ))2
k∑
i=1
c(P )m
2
/n
(P )
i
, (8)
where Y¯ (P ) is the vector of the estimated means on each dose level Y¯ (P ) = (Y¯1
(P )
, ..., Y¯k
(P )
)
′
and (σˆ(P ))2 the
estimated variances.
For the joint distribution of the test statistics we need to derive the correlation matrix of the vector
T ∗ := [(c(P1)1 )
′
Y¯ (P1), . . . , (c
(P1)
ZP1
)
′
Y¯ (P1), . . . , (c
(PW )
1 )
′
Y¯ (PW ), . . . , (c
(PW )
ZPW
)
′
Y¯ (PW )]
′
We denote by ΓP := [c
(P )
1 , ..., c
(P )
ZP
] the matrix of optimal contrast coefficients for population P and byAP ∈ Rkxn
a matrix with entries
(aij) =

1
n
(P )
i
if the j-th patient is on dose i and is in population P
0 else
,
so thatAPY = Y¯
(P ). We can then write the required covariance matrix between all contrasts as
Cov(T ∗) = Cov


Γ
′
P1
0 0
0
. . . 0
0 0 Γ
′
PW


Y¯ (P1)
...
Y¯ (PW )

 = Cov


Γ
′
P1
0 0
0
. . . 0
0 0 Γ
′
PW


AP1
...
APU
Y
 =

Γ
′
P1
AP1
...
Γ
′
PW
APW
ΣY

Γ
′
P1
AP1
...
Γ
′
PW
APW

′
=

Γ
′
P1
AP1ΣYA
′
P1
Γ
′
P1
. . . Γ
′
P1
AP1ΣYA
′
PW
Γ
′
PW
...
. . .
...
Γ
′
PW
APWΣYA
′
P1
Γ
′
P1
. . . Γ
′
PW
APWΣYA
′
PW
Γ
′
PW
 :=

ΣP1P1 . . . ΣP1PW
...
. . .
...
ΣPWP1 . . . ΣPWPW
 .
From this covariance matrix we can obtain the required correlation matrixR.
R =

RP1P1 . . . RP1PW
...
. . .
...
RPWP1 . . . RPWPW
,
where the entries of the submatrixRPQ for the correlations between tests in populations P and Q are
(ρij)
(PQ) =
K∑
l=1
[cilcjl/(n
(P )
l n
(Q)
l )
∑
P ∗∈V
n
(P∩Q∩P ∗)
l σ
2
P ∗ ]√
K∑
l=1
[cil2/n
(P )
l
2 ∑
P ∗∈V
n
(P∩P ∗)
l σ
2
P ∗ ]
K∑
l=1
[cjl2/n
(Q)
l
2 ∑
P ∗∈V
n
(Q∩P ∗)
l σ
2
P ∗ ]
.
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The cases discussed in the main part of this article correspond to U = {F, S,C} and V = {S,C}.
As in the main part of the article the form of the joint distribution, which is used to derive critical values depends
on the variance estimators in (8). Possible joint distributions are summarized in Table 1. In the general case the
degrees of freedom have to be adjusted for the possible higher number of populations as well.
A.2. Simulation results for model selection
Table 5 shows the simulation results for model selection in the case of homogeneous variances in subgroup and
complement. The Table shows the probability of choosing the correct model as the best model in the MCP-step.
The best model is defined as the model with the lowest p-value over all tested populations.
Table 5: Probability of choosing the correct dose-response model for single population (SP) and multi-
population (MP) testing methods. The best model is chosen based on the lowest significant p-value across
all populations. Probabilities shown are conditional on the global null hypothesis being rejected.
Scenario and Prevalence
same same same double double double only only only
Correct model Method 0.25 0.5 0.75 0.25 0.5 0.75 0.25 0.5 0.75
emax SP 0.50 0.51 0.50 0.37 0.44 0.45 0.26 0.33 0.40
MP-Pooled(F+S) 0.49 0.49 0.48 0.38 0.44 0.45 0.34 0.40 0.45
MP-Pooled(F+S+C) 0.48 0.48 0.49 0.37 0.43 0.46 0.34 0.41 0.46
linear SP 0.27 0.28 0.27 0.17 0.21 0.24 0.10 0.16 0.21
MP-Pooled(F+S) 0.27 0.27 0.27 0.17 0.21 0.24 0.18 0.20 0.24
MP-Pooled(F+S+C) 0.27 0.28 0.27 0.17 0.20 0.24 0.19 0.20 0.24
exponential SP 0.69 0.69 0.69 0.60 0.62 0.66 0.44 0.54 0.63
MP-Pooled(F+S) 0.68 0.69 0.68 0.58 0.62 0.67 0.54 0.60 0.65
MP-Pooled(F+S+C) 0.68 0.67 0.67 0.57 0.61 0.67 0.52 0.61 0.65
logistic SP 0.56 0.56 0.57 0.43 0.48 0.52 0.30 0.40 0.48
MP-Pooled(F+S) 0.56 0.55 0.57 0.42 0.48 0.52 0.38 0.46 0.52
MP-Pooled(F+S+C) 0.55 0.55 0.57 0.41 0.48 0.52 0.38 0.46 0.53
quadratic SP 0.76 0.76 0.76 0.64 0.69 0.71 0.43 0.60 0.67
MP-Pooled(F+S) 0.75 0.75 0.75 0.62 0.68 0.71 0.52 0.67 0.71
MP-Pooled(F+S+C) 0.74 0.75 0.74 0.62 0.68 0.71 0.51 0.66 0.71
22
References
[1] Foster JC, Taylor JM, Ruberg SJ. Subgroup identification from randomized clinical trial data. Statistics in
Medicine 2011; 30(24):2867–2880.
[2] Lipkovich I, Dmitrienko A, Denne J, Enas G. Subgroup identification based on differential effect search—a
recursive partitioning method for establishing response to treatment in patient subpopulations. Statistics in
Medicine 2011; 30(21):2601–2621.
[3] Seibold H, Zeileis A, Hothorn T. Model-based recursive partitioning for subgroup analyses. International
Journal of Biostatistics 2016; 12(1):45–63, doi:10.1515/ijb-2015-0032.
[4] Varadhan R, Wang SJ. Treatment effect heterogeneity for univariate subgroups in clinical trials: Shrinkage,
standardization, or else. Biometrical Journal 2016; 58:133–153.
[5] Rosenkranz G. Exploratory subgroup analysis in clinical trials by model selection. Biometrical Journal 2016;
58:1217–1228.
[6] Shen C, Hu Y, Li X, Wang Y, Chen PS, Buxton AE. Identification of subpopulations with distinct treatment
benefit rate using the Bayesian tree. Biometrical Journal 2016; 58(6):1357–1375.
[7] Liu J, Sivaganesan S, Laud PW, Mu¨ller P. A Bayesian subgroup analysis using collections of anova models.
Biometrical Journal 2017; 59(4):746–766.
[8] Lipkovich I, Dmitrienko A, D’Agostini RB. Tutorial in biostatistics: data-driven subgroup identification and
analysis in clinical trials. Statistics in Medicine 2017; 36(1):136–196, doi:10.1002/sim.7064.
[9] Koch GG. Discussion of p-value adjustments for subgroup analyses. Journal of Biopharmaceutical Statistics
1997; 7(2):323–331.
[10] Alosh M, Huque MF. A flexible strategy for testing subgroups and overall population. Statistics in Medicine
2009; 28(1):3–23.
[11] Ondra T, Dmitrienko A, Friede T, Graf A, Miller F, Stallard N, Posch M. Methods for identification and con-
firmation of targeted subgroups in clinical trials: a systematic review. Journal of Biopharmaceutical Statistics
2016; 26(1):99–119.
[12] Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test proce-
dures. Statistics in Medicine 2009; 28(4):586–604.
23
[13] Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical approaches for multi-
ple comparison procedures using weighted bonferroni, simes, or parametric tests. Biometrical Journal 2011;
53(6):894–913.
[14] Thomas M, Bornkamp B, Seibold H. Subgroup identification in dose-finding trials via model-based recursive
partitioning. Statistics in Medicine 2018; .
[15] Bretz F, Pinheiro JC, Branson M. Combining multiple comparisons and modeling techniques in dose-response
studies. Biometrics 2005; 61(3):738–748.
[16] Pinheiro J, Bornkamp B, Glimm E, Bretz F. Model-based dose finding under model uncertainty using general
parametric models. Statistics in Medicine 2014; 33(10):1646–1661.
[17] Pinheiro J, Bornkamp B, Bretz F. Design and analysis of dose-finding studies combining multiple comparisons
and modeling procedures. Journal of Biopharmaceutical Statistics 2006; 16(5):639–656.
[18] Xun X, Bretz F. The MCP-Mod methodology: Practical considerations and the DoseFinding R package.
Handbook of Methods for Designing, Monitoring, and Analyzing Dose-finding Trials, O’Quigley J, Iasonos
A, Bornkamp B (eds.). chap. 12, CRC Press, 2017.
[19] Hasler M. Multiple contrast tests for multiple endpoints in the presence of heteroscedasticity. The International
Journal of Biostatistics 2014; 10(1):17–28.
[20] Graf AC, Wassmer G, Friede T, Gera RG, Posch M. Robustness of testing procedures for confirmatory sub-
population analyses based on a continuous biomarker. submitted for publication 2018; .
[21] Millen BA, Dmitrienko A, Ruberg S, Shen L. A statistical framework for decision making in confirmatory
multipopulation tailoring clinical trials. Drug Information Journal 2012; 46(6):647–656.
[22] Bretz F, Ko¨nig F, Bornkamp B. Multiple test strategies for comparing several doses with a control in confirma-
tory trials. Handbook of Methods for Designing, Monitoring, and Analyzing Dose-finding Trials, O’Quigley
J, Iasonos A, Bornkamp B (eds.). chap. 16, CRC Press, 2017.
[23] Bornkamp B, Ohlssen D, Magnusson BP, Schmidli H. Model averaging for treatment effect estimation in
subgroups. Pharmaceutical Statistics 2017; 16(2):133–142.
24
Supporting Information
1 Additional simulation results for homoscedastic scenarios
1.1 Results for other data-generating models
Method global F S C
SP 0.05 0.05 - -
MP-Pooled(F+S) 0.05 0.03 0.03 -
MP-Pooled(F+S+C) 0.05 0.03 0.02 0.02
MP-MultDF(F+S) 0.05 0.03 0.02 -
MP-MultDF(F+S+C) 0.05 0.02 0.02 0.02
Table 6: Probability to reject the global null hypothesis and population null hypotheses for single popu-
lation (SP) and multi-population (MP) testing methods. Data are generated from a constant model under
homoscedasticity.
Scenario and Prevalence
same same same double double double only only only
Method Population 0.25 0.5 0.75 0.25 0.5 0.75 0.25 0.5 0.75
SP global 0.88 0.88 0.87 0.54 0.67 0.79 0.16 0.40 0.66
MP-Pooled(F+S) global 0.82 0.84 0.85 0.54 0.69 0.80 0.33 0.59 0.75
F 0.81 0.82 0.83 0.43 0.58 0.73 0.10 0.32 0.60
S 0.30 0.55 0.72 0.31 0.54 0.73 0.29 0.54 0.72
MP-Pooled(F+S+C) global 0.82 0.82 0.82 0.51 0.64 0.75 0.30 0.52 0.69
F 0.78 0.78 0.78 0.39 0.52 0.67 0.09 0.26 0.52
S 0.27 0.49 0.65 0.28 0.48 0.66 0.26 0.48 0.65
C 0.65 0.46 0.26 0.20 0.14 0.09 0.02 0.02 0.02
MP-MultDF(F+S) global 0.83 0.85 0.87 0.53 0.69 0.81 0.35 0.58 0.75
F 0.81 0.83 0.85 0.43 0.59 0.74 0.11 0.31 0.59
S 0.28 0.55 0.74 0.29 0.55 0.72 0.31 0.54 0.72
MP-MultDF(F+S+C) global 0.83 0.83 0.83 0.50 0.65 0.75 0.31 0.52 0.68
F 0.78 0.79 0.79 0.39 0.53 0.67 0.09 0.26 0.51
S 0.25 0.49 0.66 0.26 0.49 0.65 0.27 0.48 0.65
C 0.66 0.48 0.26 0.20 0.13 0.09 0.02 0.02 0.02
Table 7: Probability to reject the global null hypothesis and population null hypotheses for single pop-
ulation (SP) and multi-population (MP) testing methods. Data are generated from a linear model under
homoscedasticity.
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Scenario and Prevalence
same same same double double double only only only
Method Population 0.25 0.5 0.75 0.25 0.5 0.75 0.25 0.5 0.75
SP global 0.86 0.86 0.86 0.51 0.65 0.76 0.16 0.36 0.64
MP-Pooled(F+S) global 0.80 0.82 0.84 0.50 0.66 0.78 0.31 0.55 0.73
F 0.78 0.80 0.82 0.41 0.56 0.70 0.10 0.29 0.58
S 0.26 0.52 0.70 0.28 0.51 0.70 0.27 0.51 0.69
MP-Pooled(F+S+C) global 0.80 0.80 0.80 0.47 0.61 0.72 0.28 0.49 0.67
F 0.75 0.75 0.76 0.37 0.50 0.63 0.08 0.24 0.49
S 0.23 0.45 0.63 0.24 0.44 0.63 0.24 0.45 0.63
C 0.62 0.43 0.23 0.18 0.14 0.09 0.02 0.02 0.02
MP-MultDF(F+S) global 0.81 0.82 0.85 0.49 0.66 0.79 0.30 0.55 0.74
F 0.80 0.80 0.83 0.40 0.56 0.71 0.10 0.28 0.58
S 0.27 0.52 0.71 0.26 0.50 0.71 0.26 0.51 0.71
MP-MultDF(F+S+C) global 0.81 0.81 0.81 0.46 0.61 0.72 0.26 0.49 0.67
F 0.76 0.76 0.77 0.36 0.50 0.64 0.08 0.23 0.49
S 0.24 0.46 0.64 0.23 0.44 0.63 0.22 0.45 0.63
C 0.62 0.44 0.24 0.18 0.13 0.09 0.02 0.02 0.02
Table 8: Probability to reject the global null hypothesis and population null hypotheses for single popu-
lation (SP) and multi-population (MP) testing methods. Data are generated from an exponential model
under homoscedasticity.
Scenario and Prevalence
same same same double double double only only only
Method Population 0.25 0.5 0.75 0.25 0.5 0.75 0.25 0.5 0.75
SP global 0.95 0.95 0.95 0.64 0.80 0.88 0.20 0.49 0.78
MP-Pooled(F+S) global 0.92 0.93 0.94 0.64 0.81 0.90 0.42 0.70 0.87
F 0.92 0.92 0.93 0.54 0.72 0.84 0.13 0.41 0.73
S 0.38 0.66 0.85 0.39 0.67 0.85 0.38 0.67 0.85
MP-Pooled(F+S+C) global 0.92 0.92 0.92 0.61 0.77 0.86 0.38 0.65 0.82
F 0.90 0.90 0.90 0.50 0.67 0.80 0.11 0.36 0.66
S 0.34 0.60 0.80 0.35 0.61 0.80 0.34 0.61 0.79
C 0.80 0.60 0.35 0.27 0.19 0.11 0.02 0.02 0.02
MP-MultDF(F+S) global 0.92 0.93 0.94 0.63 0.81 0.90 0.41 0.72 0.86
F 0.92 0.92 0.93 0.53 0.72 0.85 0.13 0.41 0.73
S 0.39 0.68 0.84 0.37 0.67 0.84 0.37 0.68 0.84
MP-MultDF(F+S+C) global 0.92 0.92 0.92 0.60 0.76 0.86 0.37 0.66 0.81
F 0.90 0.90 0.90 0.49 0.66 0.80 0.11 0.35 0.66
S 0.34 0.62 0.78 0.32 0.61 0.79 0.33 0.62 0.79
C 0.80 0.60 0.34 0.25 0.20 0.11 0.02 0.02 0.02
Table 9: Probability to reject the global null hypothesis and population null hypotheses for single popu-
lation (SP) and multi-population (MP) testing methods. Data are generated from a logistic model under
homoscedasticity.
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Scenario and Prevalence
same same same double double double only only only
Method Population 0.25 0.5 0.75 0.25 0.5 0.75 0.25 0.5 0.75
SP global 0.79 0.80 0.79 0.43 0.57 0.68 0.14 0.31 0.54
MP-Pooled(F+S) global 0.73 0.75 0.77 0.42 0.58 0.70 0.26 0.47 0.65
F 0.71 0.72 0.74 0.33 0.48 0.62 0.08 0.24 0.48
S 0.22 0.42 0.61 0.23 0.43 0.62 0.23 0.43 0.61
MP-Pooled(F+S+C) global 0.72 0.71 0.72 0.39 0.53 0.64 0.24 0.41 0.57
F 0.67 0.66 0.67 0.29 0.42 0.54 0.07 0.20 0.40
S 0.19 0.37 0.53 0.20 0.37 0.54 0.20 0.37 0.54
C 0.53 0.36 0.21 0.15 0.11 0.07 0.02 0.02 0.02
MP-MultDF(F+S) global 0.72 0.74 0.78 0.42 0.58 0.69 0.25 0.47 0.65
F 0.70 0.72 0.74 0.33 0.48 0.61 0.08 0.24 0.49
S 0.23 0.42 0.62 0.23 0.44 0.60 0.22 0.43 0.61
MP-MultDF(F+S+C) global 0.72 0.72 0.73 0.40 0.53 0.62 0.23 0.41 0.58
F 0.66 0.67 0.67 0.29 0.42 0.53 0.07 0.20 0.40
S 0.20 0.36 0.54 0.19 0.38 0.52 0.19 0.37 0.54
C 0.52 0.36 0.20 0.14 0.11 0.07 0.02 0.02 0.03
Table 10: Probability to reject the global null hypothesis and population null hypotheses for single popu-
lation (SP) and multi-population (MP) testing methods. Data are generated from a quadratic model under
homoscedasticity.
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1.2 Detailed power curves
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Figure 5: Probability to reject the global null hypothesis for single population (SP) and multi-population
(MP) testing methods plotted against the treatment effect in the complement in relation to the subgroup.
Data are generated from an Emax model under homoscedasticity.
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Figure 6: Probability to reject the global null hypothesis for single population (SP) and multi-population
(MP) testing methods plotted against the treatment effect in the complement in relation to the subgroup.
Data are generated from a linear model under homoscedasticity.
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Figure 7: Probability to reject the global null hypothesis for single population (SP) and multi-population
(MP) testing methods plotted against the treatment effect in the complement in relation to the subgroup.
Data are generated from an exponential model under homoscedasticity.
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Figure 8: Probability to reject the global null hypothesis for single population (SP) and multi-population
(MP) testing methods plotted against the treatment effect in the complement in relation to the subgroup.
Data are generated from a logistic model under homoscedasticity.
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Figure 9: Probability to reject the global null hypothesis for single population (SP) and multi-population
(MP) testing methods plotted against the treatment effect in the complement in relation to the subgroup.
Data are generated from a quadratic model under homoscedasticity.
30
2 Additional simulation results for heteroscedastic scenarios
2.1 Comparison of approximate tests for other data-generating models
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Figure 10: Probability to reject the global null hypothesis for single population (SP) and multi-population
(MP) testing methods. Data are generated from a linear model under heteroscedasticity. MP-MultDF is
used to approximate the joint distribution for MP testing methods.
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Figure 11: Probability to reject the global null hypothesis for single population (SP) and multi-population
(MP) testing methods. Data are generated from an exponential model under heteroscedasticity. MP-
MultDF is used to approximate the joint distribution for MP testing methods.
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Figure 12: Probability to reject the global null hypothesis for single population (SP) and multi-population
(MP) testing methods. Data are generated from a logistic model under heteroscedasticity. MP-MultDF is
used to approximate the joint distribution for MP testing methods.
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Figure 13: Probability to reject the global null hypothesis for single population (SP) and multi-population
(MP) testing methods. Data are generated from a quadratic model under heteroscedasticity. MP-MultDF
is used to approximate the joint distribution for MP testing methods.
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2.2 Comparison of multi-population MCP to single population MCP for other
data-generating models
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Figure 14: Probability to reject the global null hypothesis for single population (SP) and multi-population
(MP) testing methods. Data are generated from a linear model under heteroscedasticity. MP-MultDF is
used to approximate the joint distribution for MP testing methods.
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Figure 15: Probability to reject the global null hypothesis for single population (SP) and multi-population
(MP) testing methods. Data are generated from an exponential model under heteroscedasticity. MP-
MultDF is used to approximate the joint distribution for MP testing methods.
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Figure 16: Probability to reject the global null hypothesis for single population (SP) and multi-population
(MP) testing methods. Data are generated from a logistic model under heteroscedasticity. MP-MultDF is
used to approximate the joint distribution for MP testing methods.
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Figure 17: Probability to reject the global null hypothesis for single population (SP) and multi-population
(MP) testing methods. Data are generated from a quadratic model under heteroscedasticity. MP-MultDF
is used to approximate the joint distribution for MP testing methods.
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